Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Arthritis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Arthritis Other
    Canakinumab Approved in EU for Patients 4 Years and Older With Cryopyrin-Associated Periodic Syndromes - (DGNews)
    Canakinumab Gives Faster, Greater Pain Relief in Refractory Gout Patients: Presented at ACR/ARHP - (DGDispatch)
    Previous Urate-Lowering Therapy Plus Febuxostat Lowers Urate Levels, Number of Flares in Patients With Gout: Presented at ACR/ARHP - (DGDispatch)
    Canakinumab Therapy Shows Promise for Systemic Juvenile Idiopathic Arthritis: Presented at AAP - (DGDispatch)
    New Interleukin-12/23 Monoclonal Antibody Effective Against Moderate to Severe Psoriasis: Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Arthritis Other
      Molecular Mechanism of Cardiovascular Disease in Inflammatory Arthritis
      Getting to the Root of Gout and Hyperuricemia: Core Principles in Diagnosis and Management for Rheumatologists
      Ankylosing Spondylitis
      Psoriatic Arthritis
      The Epidemiology of Increased Cardiovascular Death in Inflammatory Arthritis

      Webcasts/CME archive

       Recent cases - Arthritis Other
        Papular Xanthomas and Erosive Arthritis in a 3 Year Old Girl, is This a New MRH Variant?
        Idiopathic Destructive Arthritis of the Shoulder
        Superior Dislocation of the Patella: A Case Report
        Concurrent Reactive Arthritis and Myelitis - A Case Report
        Infectious Arthritis of the Knee Caused by Mycobacterium Terrae: A Case Report

        Cases archive
          




        my personal edition > arthritis other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Infliximab And Etanercept Both Effective In Treating Ankylosing Spondylitis: Presented at ACR

        By Emma Hitt

        NEW ORLEANS, LA -- October 30, 2002 -- Infliximab (Remicade) and etanercept (Embrel) both appear to be effective in treating ankylosing spondylitis (AS), according to the findings of two new phase III randomized trials

        Dr. Jan Brandt, with the Benjamin Franklin Hospital, Free University, Berlin, Germany, and colleagues presented their findings at the American College of Rheumatology (ACR) 66th Annual Scientific Meeting here on Monday.

        Previous data had suggested that infliximab, a monoclonal antibody to TNF-alpha, might have efficacy over three months in patients with active and severe AS, but the researchers point out that the long-term benefit is uncertain.

        Dr. Brandt and colleagues conducted a 54-week randomized trial of 69 patients. Of these, just over half of those taking infliximab experienced a 50 percent regression of disease activity compared to only 9 percent of placebo (p<0.001) during that time.

        The researchers report that the magnitude of improvement was sustained in every outcome measure assessed until week 54. A total of 77 percent of patients participated until the end of the trial.

        The results are "a major breakthrough" in the treatment of AS, conclude the researchers, although they point out that infliximab may cause "uncommon but potentially untoward side effects." Consequently, they recommend that the treatment be performed in cooperation with experienced rheumatologic centers.

        Their second study, an intention-to-treat primary efficacy analysis, suggested that etanercept may also benefit patients with AS. Eight out of 14 patients (57 percent) treated with etanercept achieved a 50 percent regression of disease activity at week 6 compared to only one of 16 (6 percent) patients taking placebo (p=0.004), they found.

        "In comparison to infliximab, improvement starts (more slowly) and is maintained for a shorter period of time upon treatment with etanercept," they point out. In contrast, etanercept caused fewer side effects than did infliximab.

        "Taken together, etanercept seems to be another promising treatment option for patients with active AS," the researchers conclude.

        The infliximab study was funded by Essex Pharma, Munich, Germany, and the etanercept study was funded by Wyeth Immunex, Munster, Germany.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send